We are live on ! Find out more
BGLC icon

BioNexus Gene Lab
BGLC

3 hedge funds and large institutions have $27.2K invested in BioNexus Gene Lab in 2026 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

5,373% more capital invested

Capital invested by funds: $497 → $27.2K (+$26.7K)

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

50% more funds holding

Funds holding: 2 → 3 (+1)

0.59% more ownership

Funds ownership: 0.01% → 0.6% (+0.59%)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 1

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
–
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$31.1K
2
CIAM
Caitong International Asset Management
Hong Kong
+$2

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$283
2
Wells Fargo
Wells Fargo
California
-$2

BGLC Hedge Fund Activity: Q2 2026 in Review

3 of the 8,336 institutional investors tracked by Wall St. Rank reported a position in BioNexus Gene Lab (BGLC) for Q2 2026, worth a combined $27.2K — up 5,373% from $497 a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new BGLC positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $31.1K. The largest seller was UBS Group, cutting an estimated $283.

  • 3 institutional investors held BioNexus Gene Lab (BGLC) as of Q2 2026, up from 2 in Q1 2026.
  • Funds reported $27.2K of BioNexus Gene Lab stock for Q2 2026, up 5,373% quarter-over-quarter.
  • 2 funds opened new BioNexus Gene Lab positions in Q2 2026 and 1 closed out, a net change of +1 holder.
  • The largest BioNexus Gene Lab buyer in Q2 2026 was HRT Financial, an estimated $31.1K added.
  • The largest BioNexus Gene Lab seller in Q2 2026 was UBS Group, an estimated $283 sold.

Based on aggregated 13F filings for Q2 2026.